Bioequivalence and Bioavailability Forum 14:38 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

joosefupas
Junior

Italy,
2018-11-08 11:00

Posting: # 19548
Views: 249
 

 Class I BCS based biowaiver with different amounts of API between T and R [Dissolution / BCS / IVIVC]

Hello everyone,

I have already googled around the web but couldn't find any answers thus I'll see if anyone can help here!

ICH M9 draft guidance states that “BCS-based biowaivers are applicable to drug products where the drug substance(s) (thus APIs) in test and reference products are identical (e.g. same salt, ester, isomer or mixture of isomers from that in the reference product).

My question now is, what about different API doses/amount between test and reference though?
More specifically our test product contains the exact double amount of APIs (both BCS Class I drugs) of the reference product (1000/130mg of paracetamol/caffeine TEST vs 500/65mg REFERENCE).

Given the API amount difference between T and R do you think a BCS based biowaiver application would still be applicable?

Thanks a lot in advance for the great support

Joosé
Obinoscopy
Regular

Nigeria,
2018-11-10 08:25

@ joosefupas
Posting: # 19560
Views: 165
 

 Class I BCS based biowaiver with different amounts of API between T and R

Hi Joose,

» Given the API amount difference between T and R do you think a BCS based biowaiver application would still be applicable?

No I don't think so. This is because they are not pharmaceutically equivalent.

This is even stated on the draft ICH M9 Guideline that you referenced. It can be found on lines 121 - 124 where eligibility for BCS based Biowaivers was discussed. Here's the excerpt:

A drug product is eligible for a BCS-based biowaiver provided that the drug substance(s) satisfy the criteria regarding solubility and permeability (BCS Class I and III), the drug product is an immediate-release oral dosage form with systemic action, and the drug product is a dosage form that is pharmaceutically equivalent to the reference product

For two products to be pharmaceutically equivalent, they must be of the same amount. I think some regulatory authorities allow a difference of 5% in the amount. But for 100% difference, no way.

The route you can go would be multiple strength biowaiver. However you have to check that the excipients are in the same proportion with the actives.

Regards

Scopy
joosefupas
Junior

Italy,
2018-11-12 09:49

@ Obinoscopy
Posting: # 19565
Views: 107
 

 Class I BCS based biowaiver with different amounts of API between T and R

Dear Obinoscopy,

thanks a lot for clarifying it this was really helpful!

Regards

Joose
Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
18,883 posts in 4,027 threads, 1,271 registered users;
online 24 (0 registered, 24 guests [including 22 identified bots]).

Those who make no mistakes are making the biggest mistakes of all –
they are attempting nothing new.    Anthony de Mello

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed